12 assets in Opiate Dependence

Therapeutic assets addressing Opiate Dependence, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Buprenorphine Opiate Dependence	Erin Winstanley	P4	BBB (76)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Opiate Dependence	Jacques E. Chelly	P2	BB (64)
Naltrexone Opiate Dependence	Inventage Lab., Inc.	P1	B (57)
Naproxen Opiate Dependence	Northwestern University	P2	CCC (53)
Tirzepatide Opiate Dependence	T. John Winhusen, PhD	P2	CCC (53)
Nepenthe Opiate Dependence	Lyndra Inc.	P1	CC (47)
ivl3004 Opiate Dependence	Inventage Lab., Inc.	P1	CC (43)
ivl4002 Opiate Dependence	Inventage Lab., Inc.	P1	CC (43)
Izaflortaucipir Opiate Dependence	University of Pennsylvania	Early P1	CC (43)
Lacosamide Opiate Dependence	Indiana University	P1	CC (43)
Levomethadone Hydrochloride Opiate Dependence	Lyndra Inc.	P1	CC (43)
Betacarotene Opiate Dependence	Yale University	Early P1	C (39)